SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
申请人:Eastwood Paul Robert
公开号:US20110046097A1
公开(公告)日:2011-02-24
The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors
申请人:Eastwood Paul Robert
公开号:US08450341B2
公开(公告)日:2013-05-28
The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
申请人:Almirall, S.A.
公开号:EP2280953B1
公开(公告)日:2012-05-09
US8450341B2
申请人:——
公开号:US8450341B2
公开(公告)日:2013-05-28
[EN] NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS SUBSTITUÉS INDOLIN-2-ONE ET UTILISATION DE CES DERNIERS EN TANT QU'INHIBITEURS DE KINASE ACTIVÉS PAR LE MITOGÈNE P39
申请人:ALMIRALL SA
公开号:WO2009132774A1
公开(公告)日:2009-11-05
This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.